Vericel Corp banner

Intrinsic Value

The intrinsic value of Vericel Corp (ATQP) under the Base Case is 44.6 EUR per share. Compared with the current market price of 51.5 EUR, the stock appears Overvalued by 13% .

The intrinsic value is calculated using the DCF method.

Do our valuations actually work? See backtest results .

ATQP Intrinsic Value
€44.6
Overvaluation 13%
Intrinsic Value
Price €51.5

ATQP is valued in line with its history. A premium of this size has been typical over the past 5 years.

Monitor ATQP
Get notified when the price drops
Track Buy Zone
20% below Intrinsic Value €35.68
Get notified when the price drops into your buy zone
Current Price €51.5
Intrinsic Value €44.6
Margin of Safety 20% €35.68
Or choose another margin of safety
0% below Intrinsic Value
10% below Intrinsic Value
30% below Intrinsic Value
40% below Intrinsic Value
50% below Intrinsic Value
Custom
Alternatives to ATQP

Fundamental Analysis

What Vericel Does

Biotechnology Health Care

Vericel Corp makes and sells specialty cell-therapy products for difficult orthopedic and burn injuries. Its main products are used by surgeons and hospitals to treat damaged knee cartilage and severe burns, where standard treatments may not work as well. The company focuses on very specific medical problems instead of broad drug categories.

Headquarters
United States of America US
Employees
398
IPO date
Feb 4, 1997
Read the full company overview
View Company Overview
Financials
Efficiency

Earnings Waterfall
Vericel Corp

Wall St Price Targets

Capital Returns

Competitive Landscape

Ownership

VCEL Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one ATQP stock?

The intrinsic value for Vericel Corp (ATQP) under the Base Case is 44.6 EUR.

Is ATQP stock undervalued or overvalued?

Compared with the current market price of 51.5 EUR, the stock appears Overvalued by 13% .

Back to Top